Stryker Corporation (NYSE: SYK) has witnessed substantial gains in the year-to-date period. Shares of the company have rallied 18.6% compared with 13.4% growth of the industry. The S&P 500 Composite has risen 20.1% during the same time frame.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for investors at the moment.
Headquartered in Kalamazoo, MI, Stryker is one of the world's largest medical device companies operating in the global orthopedic market. The company has three business segments — Orthopaedics, MedSurg and Neurotechnology & Spine.
Strength in Stryker's flagship Mako Total Knee Platform, which enables surgeons to do pre-operative planning and precise surgeries, looks promising. The company is also adopting several cost-cutting measures, including restructuring plans. Its prospects seem promising on the back of strong customer demand for its existing products as well as new launches. Stryker's recent acquisitions also raise optimism about the stock.
Image Source: Zacks Investment Research
Catalysts for Stryker's Growth
The surge in the company's share price can be attributed to its advanced robotic arm-assisted surgery platform, Mako, a strong product lineup and strategic acquisitions. The positive sentiment, driven by a solid second-quarter fiscal 2024 performance and promising business potential, is expected to continue aiding it.
Stryker ended the second quarter on a high note, with both earnings and revenues showing year-over-year improvement. The company saw robust performance in the U.S. market, particularly in Instruments, Medical, Endoscopy, Trauma and Extremities, and Mako, which likely boosted the stock's price.
SYK has increased its revenue and earnings forecasts for fiscal 2024, likely attracting investor interest. The company now anticipates organic revenue growth of 9-10% for fiscal 2024, up from the previous guidance of 8.5-9.5%. Adjusted ...
